While Washington Tackles Opioid Abuse Epidemic, Hepatitis C Treatment Remains Unaffordable

If Washington wants to do something about the public health issues left behind by the opioid abuse epidemic, it might have to start doing something about prescription-drug costs.

Used syringes are discarded at a needle exchange clinic where users can pick up new syringes and other clean items for those dependent on heroin.
National Journal
Caitlin Owens
Add to Briefcase
See more stories about...
Caitlin Owens
Aug. 18, 2015, 1 a.m.

Big names in Wash­ing­ton are in­creas­ingly join­ing the fight to com­bat the rise of opioid and heroin ab­use, but the con­ver­sa­tion around the is­sue is miss­ing half the prob­lem.

On Monday, the White House an­nounced an ini­ti­at­ive to curb heroin use by ad­dress­ing it as both a pub­lic-safety and pub­lic-health is­sue, pair­ing law en­force­ment with ac­cess to treat­ment for ad­dicts. This builds on mo­mentum with­in Con­gress and talk among 2016 pres­id­en­tial hope­fuls sur­round­ing the re­duc­tion of na­tion­al opioid drug ad­dic­tion.

But largely ex­cluded from the dis­cus­sion is what to do about those liv­ing with the con­sequences of their ad­dic­tion and the pub­lic health con­cern that presents. For many, ac­cess to treat­ment for dis­ease con­trac­ted through drug use is un­af­ford­able. Al­though there is med­ic­a­tion on the mar­ket to treat hep­at­it­is C — a dis­ease com­mon among drug users — its cost of­ten makes it un­avail­able to the sick.

“An un­qual­i­fied yes,” said Matt Salo, ex­ec­ut­ive dir­ect­or of the Na­tion­al As­so­ci­ation of Medi­caid Dir­ect­ors, when asked if state Medi­caid pro­grams are strug­gling to cov­er the cost of hep­at­it­is C med­ic­a­tions. “There isn’t a Medi­caid pro­gram in the coun­try that can af­ford to cov­er the cost of treat­ment for every pa­tient.”

If Wash­ing­ton wants to do something about the pub­lic health is­sues left be­hind by the opioid ab­use epi­dem­ic, it might have to start do­ing something about pre­scrip­tion drug costs.

Sovaldi — one of few med­ic­a­tions avail­able to treat hep­at­it­is C — costs $1,000 a pill, or about $84,000 for an en­tire course of treat­ment. And while it might be an ex­treme ex­ample, it rep­res­ents a grow­ing class of spe­cialty drugs that are in­creas­ingly driv­ing up health care costs — and an un­will­ing­ness in Wash­ing­ton to do much about it.

“When you’ve got an ef­fect­ive drug that has few or no com­pet­it­ors, its very hard for pay­ers to push back,” said Larry Levitt, seni­or vice pres­id­ent of the Kais­er Fam­ily Found­a­tion. “We are alone in the world as a coun­try that re­lies more on mar­ket forces to deal with drug prices than gov­ern­ment reg­u­la­tion.”

Hep­at­it­is C med­ic­a­tion presents an in­ter­est­ing case study of strad­dling the line between an is­sue the gov­ern­ment is keen to ad­dress — opioid use — and one it does not seem to want to touch — the cost of medi­cine.

And while private in­surers pay for the treat­ment as well, of­ten the bill falls in­to the lap of the gov­ern­ment.

“The way I look at it, hep­at­it­is C is a pub­lic-health is­sue,” said Dan Mendel­son, CEO of Avalere Health, an in­de­pend­ent con­sult­ing com­pany. “It’s a dis­ease of poverty, it’s a dis­ease of ad­dic­tion, it’s a dis­ease that comes along with needle use. That is why the hep­at­it­is C cures are be­ing pur­chased largely by Medi­caid pro­grams. And also many of them are pur­chased un­der the ex­change policy — so this is gov­ern­ment policy one way or an­oth­er.

“Ul­ti­mately, the Con­gress has to de­cide wheth­er drug price con­trols are the right an­swer. In my view, that would be a mis­take,” he ad­ded.

Cures for hep­at­it­is C on the mar­ket in­clude Sovaldi and the new­er Harvoni, both made by Gilead Sci­ences Inc. Two oth­ers were ap­proved with­in the same year, and an­oth­er was ap­proved last month, ac­cord­ing to the FDA. But oth­ers are in the pipeline to mar­ket and could present price-re­du­cing com­pet­i­tion.

“The price of Gilead’s hep­at­it­is C treat­ments re­flects the sig­ni­fic­ant clin­ic­al, eco­nom­ic, and pub­lic health value of these drugs, and is com­par­able to, or in many cases less than, the cost of older, less ef­fect­ive re­gi­mens,” the drug maker wrote in a policy po­s­i­tion on its web­site.

An ex­cep­tion to in­ac­tion in Wash­ing­ton is an in­vest­ig­a­tion launched by Sens. Ron Wyden and Chuck Grass­ley last year in­to the cost of Sovaldi, which is still pending. The sen­at­ors asked the drug­maker for de­tailed pri­cing in­form­a­tion.

“Giv­en the im­pact Sovaldi’s cost will have on Medi­care, Medi­caid, and oth­er fed­er­al spend­ing, we need a bet­ter un­der­stand­ing of how your com­pany ar­rived at the price for this drug,” the law­makers said in a state­ment last Ju­ly. “In or­der for a mar­ket­place to func­tion prop­erly, it must be com­pet­it­ive, fair, and trans­par­ent. It is un­clear how Gilead set the price for Sovaldi. That price ap­pears to be high­er than ex­pec­ted giv­en the costs of de­vel­op­ment and pro­duc­tion and the steep dis­counts offered in oth­er coun­tries. An ef­fi­cient mar­ket needs in­formed con­sumers to keep costs down.”

The pres­id­ent’s budget re­quest earli­er this year in­cludes a pro­pos­al that would al­low Medi­care to ne­go­ti­ate with drug­makers over drug prices. But these ne­go­ti­ations are gen­er­ally a non­starter policy for Re­pub­lic­ans.

The heroin over­dose death rate has nearly quad­rupled over the past dec­ade, and the rise in the drug’s use is linked to the opioid paink­iller epi­dem­ic. People who are ad­dicted to opioid paink­illers are 40 times more likely to be ad­dicted to heroin.

A na­tion­al hep­at­it­is C out­break has been well doc­u­mented. Last month, The New York Times re­por­ted that in Ken­tucky, 16,000 Medi­caid re­cip­i­ents had a hep­at­it­is C dia­gnos­is last year, com­pared with only 8,000 the pre­vi­ous year (this partly re­flects a Medi­caid ex­pan­sion un­der Obama­care). Ken­tucky’s rate of hep­at­it­is C is more than sev­en times the na­tion­al av­er­age, but the state spent 7 per­cent of its Medi­caid budget treat­ing only 861 people.

While the situ­ation may be par­tic­u­larly dire in a hand­ful of states, the num­ber of cases and the cost of treat­ment is for­cing states to make dif­fi­cult de­cisions.

“States have to pri­or­it­ize treat­ment to those most in need. An ex­er­cise that would be wholly un­ne­ces­sary if the cost were af­ford­able,” Salo wrote in an email.

Gen­er­ally, “most is need” is defined as those who have already ex­per­i­enced liv­er func­tion de­teri­or­a­tion, with stage 3 or 4 liv­er fibrosis the cutoff in most states, Salo said.

It’s “harder to gauge what per­cent­age” of the pop­u­la­tion with hep­at­it­is C states can af­ford to treat, Salo wrote, “since the de­nom­in­at­or is still some­what un­known (and there are a num­ber of people who are asymp­to­mat­ic and may not even know they have it). But prob­ably safe to say it’s a fairly small per­cent­age.”

While Con­gress has not taken up any le­gis­la­tion ad­dress­ing opi­ate ad­dic­tion, the is­sue has a power­ful ad­voc­ate from Ken­tucky — Sen­ate Ma­jor­ity Lead­er Mitch Mc­Con­nell, who has made the is­sue a “ser­i­ous fo­cus … for years,” ac­cord­ing to Robert Steurer, a Mc­Con­nell spokes­per­son.

In re­sponse to hep­at­it­is C, Mc­Con­nell helped se­cure lan­guage in an ap­pro­pri­ations bill this year that would al­low states with a high in­crease in the dis­ease to work with the Cen­ters for Dis­ease Con­trol and Pre­ven­tion on us­ing fed­er­al money for needle ex­change pro­grams.

And in the House, there have been a series of hear­ings on opioid ab­use held by the En­ergy and Com­merce Com­mit­tee’s over­sight and in­vest­ig­a­tions sub­com­mit­tee.

“It is es­sen­tial to identi­fy and en­gage people who use pre­scrip­tion opioids non-med­ic­ally early be­cause the risks of be­ing in­fec­ted with HIV or hep­at­it­is C in­creases dra­mat­ic­ally once someone trans­itions to in­jec­tion drug use,” Mi­chael Bot­ti­celli, dir­ect­or of Na­tion­al Drug Con­trol Policy, wrote in a pre­pared testi­mony in May.

“It is much less ex­pens­ive to treat a per­son for just a sub­stance use dis­order early us­ing evid­ence-based treat­ment, rather than to treat a per­son with a sub­stance use dis­order and provide life­time treat­ment for HIV or a cure for hep­at­it­is C,” he ad­ded.

In blog posts dis­cuss­ing pre­scrip­tion drug spend­ing, PhRMA poin­ted that not only do new drugs help con­trol fu­ture health care costs and al­low pa­tients to live longer, health­i­er lives, but also that hep­at­it­is C treat­ments — which in­clude both Sovaldi and Harvoni and have cures rates of more than 90 per­cent — are of­ten sub­ject to steep dis­counts fol­low­ing Medi­caid ne­go­ti­ations.

While the idea of gov­ern­ment drug price ne­go­ti­ation is out there, it is not likely to be­come much more than an idea any time soon.

“There’s a sense that price reg­u­la­tion is some­what un-Amer­ic­an, even though the pub­lic is quite sup­port­ive,” Levitt said. “It in­volves a role for gov­ern­ment in the mar­ket that makes people un­com­fort­able.”

But the good news for those pay­ing for hep­at­it­is C treat­ment — and those hop­ing to ad­dress the opioid epi­dem­ic — is that its un­af­ford­ab­il­ity prob­ably won’t last forever.

“What’s in­ter­est­ing about Sovaldi is it’s a one-time treat­ment, so I think the big costs we were see­ing re­cently will drop off be­cause there was a lot of pent up de­mand for people that had hep­at­it­is C that was un­treated,” Levitt said.

But, he ad­ded, “you nev­er know when the next Sovaldi will come along either, wheth­er it’s for can­cer or heart dis­ease or HIV or MS — drug spend­ing tends to be very lumpy be­cause it’s driv­en by new block­buster drugs, which don’t come along all the time.”

What We're Following See More »
Trump Drops Ultimatum on Healthcare
10 hours ago

"President Trump delivered an ultimatum to House Republicans on Thursday night: Vote to approve the measure to overhaul the nation’s health-care system on the House floor Friday, or reject it and the president will move on to his other legislative priorities." Passage remains far from certain, however, even with a 3pm Friday vote scheduled.

Trump’s SEC Chair Nominee Faces Tough Questioning
16 hours ago

Jay Clayton, Donald Trump's nominee to lead the Securities and Exchange Commission, was grilled today during his hearing in front of the Senate Committee on Banking, Housing, and Urban Affairs. In question were his extensive ties to Wall Street and his potential conflicts of interest. During his hearing, Clayton promised he would not show favoritism to anyone. Clayton's financial disclosure revealed that Clayton "raked in $7.6 million in the year leading up to his nomination, buoyed by a client roster that included big banks such as Goldman Sachs. President Donald Trump has picked Goldman alums for several regulatory roles in his administration."

Health Vote Postponed
16 hours ago
Senators Press Sonny Perdue on Budget Cuts
17 hours ago

"Former Georgia governor Sonny Perdue, President Trump’s pick to lead the Agriculture Department, faced pointed questions about the administration’s proposed cuts to rural assistance programs during his otherwise friendly Senate confirmation hearing Thursday. Throughout the hearing, Perdue affirmed his commitment to several programs that could face cuts due to Trump’s budget: the Rural Utilities Service; the Natural Resource Conservation Center; and various agricultural research programs," even as the president's budget would cut his agency by 20 percent.

No Deal on Healthcare
18 hours ago

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.